Business Context and Reporting Period
Company: Colgate-Palmolive Company
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2003
Business Overview: A leading global consumer products company founded in 1806, operating in over 200 countries. The Company manages two primary segments: Oral, Personal, Household Surface and Fabric Care; and Pet Nutrition (Hill's). It is a global leader in Oral Care and the specialty pet nutrition market.
Key Financial Metrics (2003)
| Metric | 2003 Value | 2002 Value |
|---|---|---|
| Net Sales | $9,903.4 million | $9,294.3 million |
| Gross Profit Margin | 55.0% | 54.6% |
| Operating Profit | $2,166.0 million | $2,013.1 million |
| Net Income | $1,421.3 million | $1,288.3 million |
| Diluted EPS | $2.46 | $2.19 |
| Operating Cash Flow | $1,767.7 million | $1,611.2 million |
| Free Cash Flow (before dividends) | $1,465.6 million | $1,267.5 million |
| Total Debt | $3,102.9 million | $3,603.9 million |
| Long-Term Debt | $2,999.3 million | $3,509.3 million |
| Cash and Equivalents | $265.3 million | $167.9 million |
Material Changes vs. Prior Period
- Revenue Growth: Worldwide net sales increased 6.5% to $9.9 billion, driven by 3.5% volume growth, 0.5% price increases, and a 2.5% positive foreign exchange impact.
- Profitability: Operating profit rose 8% to $2.17 billion. Gross profit margin improved to 55.0% despite higher material costs, aided by supply chain optimization and a focus on high-margin businesses.
- Segment Performance:
- Europe: Sales surged 16.0% (driven by a stronger Euro) and operating profit grew 19%.
- Asia/Africa: Sales increased 13.5% and operating profit grew 21%.
- Pet Nutrition: Sales grew 11.0% and operating profit increased 17%.
- North America: Sales declined 1.0% due to price declines, though volume grew 0.5%.
- Divestitures and Restructuring: The Company sold non-core European detergent and soap brands for $127.6 million, recognizing a $107.2 million gain. Concurrently, it incurred $59.3 million in restructuring costs related to manufacturing regionalization.
- Debt Reduction: Total debt decreased by approximately $500 million due to strong free cash flow and proceeds from divestitures.
Guidance, Outlook, and Risks
- Acquisition: In December 2003, the Company agreed to acquire GABA Holding AG, a European oral care company, for approximately $645 million to $846.5 million. Funding will utilize debt and cash, potentially reducing 2004 share repurchases.
- Outlook: Management expects 2004 market conditions to be similar to 2003, with continued growth driven by new product introductions and economic development in emerging markets.
- Key Risks:
- Legal Contingencies (Brazil): Significant ongoing proceedings regarding the 1995 Kolynos acquisition. Risks include a potential $90 million Central Bank fine, a $35 million tax assessment, and criminal charges against officers. Management intends to appeal vigorously.
- Foreign Exchange: Approximately 70% of sales are outside the U.S.; currency fluctuations (e.g., Euro, Latin American currencies) significantly impact reported results.
- Competition: Intense global competition from multinational rivals and private label brands.
Investor Verification Checklist
- Brazilian Legal Exposure: Verify the status of the Central Bank fine ($90M) and tax assessment ($35M) and the likelihood of the Company prevailing on appeal.
- GABA Acquisition Integration: Monitor the closing of the GABA Holding AG acquisition and the impact on leverage ratios given the planned debt financing.
- Foreign Currency Sensitivity: Assess the impact of the strengthening Euro on 2003 results versus potential volatility in Latin American currencies for 2004.
- Restructuring Costs: Confirm the total expected cost of restructuring activities (estimated at $70.7 million total) and the timeline for completion.
- Share Repurchases: Note the anticipated decline in 2004 share buybacks due to the GABA acquisition funding requirements.